The Open UniversitySkip to content
 

Role Of d16HER2 Splice Variant In Breast Cancer Stem Cells

Castagnoli, Lorenzo (2018). Role Of d16HER2 Splice Variant In Breast Cancer Stem Cells. PhD thesis The Open University.

Full text available as:
[img]
Preview
PDF (Version of Record) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (5MB) | Preview
Google Scholar: Look up in Google Scholar

Abstract

The transmembrane tyrosine kinase receptor HER2 is overexpressed in about 20% of human breast cancers (BCs). Evidence suggests that the co-existence of the full-length/wild-type HER2 oncoprotein (WTHER2) with its altered isoforms increases the heterogeneity of HER2 overexpressing (HER2+) disease thus affecting its biology and treatment response. We found that ~90% of HER2+ BC patients express a WTHER2 isoform characterized by the lack of exon 16 (d16HER2), a peculiar absence promoting the generation of stable and constitutively activated HER2 homodimers. Since the impact of d16HER2 in HER2+ BC disease was debatable at the beginning of my Ph.D. project, I focused my studies to investigate and unravel d16HER2 implication in HER2+ BC aggressiveness, susceptibility to specific biotherapies and stemness. Our in vitro and in vivo findings made clearer the potent oncogenicity driven by d16HER2 variant vs WTHER2 unveiling its direct functional interplay with the activated tyrosine kinase SRC that was found to be coupled with d16HER2 expression/activity in HER2+ BCs. Further, pre-clinical and clinical data indicated that d16HER2 activation determines the greatest benefits from trastuzumab administration in HER2+ BCs. Additionally, our results pointed to a crucial d16HER2 role in the regulation of the BC stem cells (BCSCs) activity through its functional interaction with the NOTCH family members. We also observed that the higher trastuzumab efficiency inhibits the growth/progression of HER2+ BCs characterized by an activated d16HER2 signature was consistent with its ability to target BCSCs effectively. Finally, our data revealed that d16HER2 expression/activity in driving tumour aggressiveness could be extended also to HER2+ gastric cancers.

The results of my Ph.D. thesis contribute to highlight the crucial role played by d16HER2 in the aggressiveness, sensitivity to trastuzumab and stemness of HER2+ BCs vs the WTHER2 receptor.

Item Type: Thesis (PhD)
Copyright Holders: 2017 The Author
Academic Unit/School: Faculty of Science, Technology, Engineering and Mathematics (STEM)
Associated Research Centre: Fondazione IRCCS 'Istituto Nazionale dei Tumori'
Item ID: 53114
Depositing User: Lorenzo Castagnoli
Date Deposited: 09 Mar 2018 11:14
Last Modified: 02 May 2018 14:38
URI: http://oro.open.ac.uk/id/eprint/53114
Share this page:

Download history for this item

These details should be considered as only a guide to the number of downloads performed manually. Algorithmic methods have been applied in an attempt to remove automated downloads from the displayed statistics but no guarantee can be made as to the accuracy of the figures.

Actions (login may be required)

Policies | Disclaimer

© The Open University   contact the OU